Table 2.
Baseline patient clinical characteristics
| Characteristics | Spironolactone (n=77) | Chlorthalidone (n=77) |
| Age (yr) | 57 (14) | 56 (15) |
| Male, n (%) | 53 (69) | 53 (69) |
| BMI (kg/m2) | 29.5 (5.0) | 27.6 (3.8) |
| Smoking, n (%) | ||
| Never smoked | 37 (48) | 37 (48) |
| Ex-smoker | 35 (46) | 29 (38) |
| Current smoker | 5 (6) | 11 (14) |
| Office systolic BP (mm Hg) | 134 (14) | 135 (14) |
| Office diastolic BP (mm Hg) | 80 (10) | 81 (9) |
| Heart rate (bpm) | 72 (14) | 71 (12) |
| Serum creatinine (mg/dl) | 1.45 (0.46) | 1.32 (0.35) |
| eGFR (ml/min per 1.73 m2) | 52 (16) | 57 (15) |
| Hemoglobin (g/dl) | 13.6 (1.3) | 13.6 (1.6) |
| Cholesterol (mg/dl) | 191 (38) | 184 (40) |
| Serum potassium (mEq/L) | 4.4 (0.4) | 4.5 (0.3) |
| No. of patients on treatment, n (%) | ||
| ACE inhibitors | 42 (55) | 43 (56) |
| Angiotensin receptor blockers | 35 (45) | 34 (44) |
| Beta blockers | 13 (17) | 13 (17) |
| Calcium channel blockers | 33 (43) | 23 (30) |
| Alpha blockers | 13 (17) | 6 (8) |
| Statins | 31 (40) | 35 (45) |
| Etiology of kidney disease, n (%) | ||
| Known pathology | 60 (78) | 59 (77) |
| Primary GN | 29 (48) | 20 (34) |
| Interstitial nephropathies | 5 (8) | 10 (17) |
| Hereditary nephropathy | 15 (25) | 16 (27) |
| Kidney vascular disease | 2 (5) | 4 (7) |
| Hypertensive nephropathy | 4 (7) | 3 (5) |
| Secondary GN | 0 | 3 (5) |
| Other multisystem disease | 2 (3) | 2 (3) |
| Other | 3 (5) | 1 (2) |
| Cardiovascular history, n (%) | ||
| Previous myocardial infarction | 1 (1) | 4 (5) |
| Previous hypertension | 67 (87) | 64 (83) |
| Previous stroke | 1 (1) | 1 (1) |
Values are mean±SD for continuous data. Categorical data are number (percentage). BMI, body mass index; ACE, angiotensin converting enzyme.